1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Lilly/AstraZeneca's Lanabecestat Becomes Latest BACE Inhibitor Casualty

 
• By Eleanor Malone

Just weeks after Johnson & Johnson halted development of its BACE inhibitor for Alzheimer's and a few months after Merck & Co failed at Phase III, Lilly and AstraZeneca end trials of lanabecestat.

magnetic resonance image (MRI) of the brain human

AstraZeneca PLC and Eli Lilly & Co. are to discontinue Phase III trials of their oral beta-site amyloid precursor protein cleaving enzyme (BACE) inhibitor lanabecestat in Alzheimer's disease. The two trials, one in early Alzheimer's and the other in mild Alzheimer's dementia, were stopped for futility on the recommendation of an independent data monitoring committee, which said they were unlikely to meet their primary endpoints on completion.

The field of BACE inhibition in Alzheimer's is littered with casualties, most recently Johnson & Johnson's atebecestat, which was discontinued because of liver safety issues.(Also see "More Alzheimer's Pain As J&J Pulls Plug On BACE Inhibitor" - Scrip, 18 May, 2018.) Merck & Co's verubecestat was also halted earlier this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.